Graft-Versus-Leukemia Effect and Graft-Versus-Host Disease Can Be Differentiated by Cytotoxic Mechanisms in a Murine Model of Allogeneic Bone Marrow Transplantation.

Slides:



Advertisements
Similar presentations
Induction of Graft-versus-Leukemia (GVL) Effect without Graft-versus-Host Disease (GVHD) by Pretransplant Donor Treatment with Immunomodulators  Shoshana.
Advertisements

Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions by Natalie Hartmann,
Reduced Graft-versus-Host Disease in C3-Deficient Mice Is Associated with Decreased Donor Th1/Th17 Differentiation  Qing Ma, Dan Li, Roza Nurieva, Rebecca.
Host-Derived CD8+ Dendritic Cells Protect Against Acute Graft-versus-Host Disease after Experimental Allogeneic Bone Marrow Transplantation  Michael Weber,
High-Risk Acute Lymphoblastic Leukemia Cells with bcr-abl and Ink4a/Arf Mutations Retain Susceptibility to Alloreactive T Cells  Faith M. Young, Andrew.
Secondary Lymphoid Organs Contribute to, but Are Not Required for the Induction of Graft-versus-Host Responses following Allogeneic Bone Marrow Transplantation:
Expression of Chemokines in GVHD Target Organs Is Influenced by Conditioning and Genetic Factors and Amplified by GVHR  Markus Y. Mapara, Corinna Leng,
Influence of Donor Microbiota on the Severity of Experimental Graft-versus-Host- Disease  Isao Tawara, Chen Liu, Hiroya Tamaki, Tomomi Toubai, Yaping Sun,
Host-Derived Interleukin-18 Differentially Impacts Regulatory and Conventional T Cell Expansion During Acute Graft-Versus-Host Disease  Robert Zeiser,
IL-2–Targeted Therapy Ameliorates the Severity of Graft-versus-Host Disease: Ex Vivo Selective Depletion of Host-Reactive T Cells and In Vivo Therapy 
Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers by Andrea.
Juyang Kim, Wongyoung Kim, Hyun J. Kim, Sohye Park, Hyun-A
Differential Effects of Gut-Homing Molecules CC Chemokine Receptor 9 and Integrin-β7 during Acute Graft-versus-Host Disease of the Liver  Alina Schreder,
A New Strategy for Treatment of Autoimmune Diseases in Chimeric Resistant MRL/lpr Mice by Kenji Takeuchi, Muneo Inaba, Shigeo Miyashima, Ryokei Ogawa,
CCR2 is required for CD8-induced graft-versus-host disease
by Yoshinobu Maeda, Pavan Reddy, Kathleen P
Ping Zhang, Jieying Wu, Divino Deoliveira, Nelson J. Chao, Benny J
Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.
by Norman Nausch, Ioanna E
Mesenchymal Stem Cells (MSCs) Attenuate Cutaneous Sclerodermatous Graft-Versus- Host Disease (Scl-GVHD) through Inhibition of Immune Cell Infiltration.
IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation by Christoph Bucher, Lisa Koch, Christine.
B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality by Rachelle G. Veenstra, Ryan Flynn, Katharina.
LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice  Dapeng Wang, Cristina Iclozan, Chen Liu, Changqing Xia, Claudio.
Cytosine-Phosphorothionate-Guanine Oligodeoxynucleotides Exacerbates Hemophagocytosis by Inducing Tumor Necrosis Factor–Alpha Production in Mice after.
A Role for TNF Receptor Type II in Leukocyte Infiltration into the Lung during Experimental Idiopathic Pneumonia Syndrome  Gerhard C. Hildebrandt, Krystyna.
The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease by Shan He, Fang.
by Sheng F. Cai, Xuefang Cao, Anjum Hassan, Todd A
Lack of the adhesion molecules P-selectin and intercellular adhesion molecule-1 accelerate the development of BCR/ABL-induced chronic myeloid leukemia-like.
PreImplantation Factor Reduces Graft-versus-Host Disease by Regulating Immune Response and Lowering Oxidative Stress (Murine Model)  Yehudith Azar, Reut.
IL-17 Gene Ablation Does Not Impact Treg-Mediated Suppression of Graft-Versus-Host Disease after Bone Marrow Transplantation  Lucrezia Colonna, Mareike.
by Oleg I. Krijanovski, Geoffrey R. Hill, Kenneth R
Induction of Graft-versus-Leukemia (GVL) Effect without Graft-versus-Host Disease (GVHD) by Pretransplant Donor Treatment with Immunomodulators  Shoshana.
The Synthetic Triterpenoid, CDDO, Suppresses Alloreactive T Cell Responses and Reduces Murine Early Acute Graft-versus-Host Disease Mortality  Kai Sun,
Evelyn C. Nieves, Tomomi Toubai, Daniel C
Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing.
Pharmacologic Expansion of Donor-Derived, Naturally Occurring CD4+Foxp3+ Regulatory T Cells Reduces Acute Graft-versus-Host Disease Lethality Without.
Tatjana Banovic, Kelli P. A. MacDonald, Kate A. Markey, Edward S
The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.
Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease by Tangsheng Yi, Dongchang Zhao, Chia-Lei.
Inhibition of Cathepsin S Reduces Allogeneic T Cell Priming but Not Graft-versus-Host Disease Against Minor Histocompatibility Antigens  Hisaki Fujii,
Sequential Expression of Adhesion and Costimulatory Molecules in Graft-versus-Host Disease Target Organs after Murine Bone Marrow Transplantation across.
Activated Allogeneic NK Cells as Suppressors of Alloreactive Responses
Blocking Activator Protein 1 Activity in Donor Cells Reduces Severity of Acute Graft- Versus-Host Disease through Reciprocal Regulation of IL-17–Producing.
Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice  Yongxia Wu, David Bastian, Steven Schutt, Hung Nguyen,
Hydrodynamic Delivery of Human IL-15 cDNA Increases Murine Natural Killer Cell Recovery after Syngeneic Bone Marrow Transplantation  Isabel Barao, Maite.
T helper17 Cells Are Sufficient But Not Necessary to Induce Acute Graft-Versus-Host Disease  Cristina Iclozan, Yu Yu, Chen Liu, Yaming Liang, Tangsheng.
Volume 18, Issue 3, Pages (March 2003)
The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.
Host Basophils Are Dispensable for Induction of Donor T Helper 2 Cell Differentiation and Severity of Experimental Graft-versus-Host Disease  Isao Tawara,
Effector Cells Derived from Host CD8 Memory T Cells Mediate Rapid Resistance against Minor Histocompatibility Antigen-Mismatched Allogeneic Marrow Grafts.
A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation, and Onset of Graft-versus-Host Disease in.
Dynamic Change and Impact of Myeloid-Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice  Dapeng Wang, Yu Yu, Kelley Haarberg,
Mammalian Target of Rapamycin Inhibitors Permit Regulatory T Cell Reconstitution and Inhibit Experimental Chronic Graft-versus-Host Disease  Haruko Sugiyama,
Volume 10, Issue 5, Pages (May 1999)
Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host.
Recipient B Cells Are Not Required for Graft-Versus-Host Disease Induction  Catherine Matte-Martone, Xiajian Wang, Britt Anderson, Dhanpat Jain, Anthony.
Interleukin-18 and the Costimulatory Molecule B7-1 Have a Synergistic Anti-Tumor Effect on Murine Melanoma; Implication of Combined Immunotherapy for.
CD25 expression distinguishes functionally distinct alloreactive CD4+ CD134+ (OX40+) T-cell subsets in acute graft-versus-host disease  Philip R Streeter,
Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation  Jian-Ming Li, Edmund K.
Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD4+25+ T cells to allow an effective graft-versus-leukemia response 
Brile Chung, Eric Dudl, Akira Toyama, Lora Barsky, Kenneth I. Weinberg 
Early Vaccination with Tumor Lysate-Pulsed Dendritic Cells after Allogeneic Bone Marrow Transplantation Has Antitumor Effects  Jeffrey S. Moyer, Gabriel.
Raimon Duran-Struuck, Isao Tawara, Kathi Lowler, Shawn G
Specific donor Vβ-associated CD4+ T-cell responses correlate with severe acute graft- versus-host disease directed to multiple minor histocompatibility.
Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect  Shawn G Clouthier,
Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution  Maria Gendelman, Maryam Yassai,
Induction of Lethal Graft-versus-Host Disease by Anti-CD137 Monoclonal Antibody in Mice Prone to Chronic Graft-versus-Host Disease  Wonyoung Kim, Juyang.
Roles of CD28, CTLA4, and Inducible Costimulator in Acute Graft-versus-Host Disease in Mice  Jun Li, Kenrick Semple, Woong-Kyung Suh, Chen Liu, Fangping.
IL-17A mediates cutaneous GVHD
Pretreatment of donor T cells with a c-Rel antagonist does not impair GVT activity. Pretreatment of donor T cells with a c-Rel antagonist does not impair.
Presentation transcript:

Graft-Versus-Leukemia Effect and Graft-Versus-Host Disease Can Be Differentiated by Cytotoxic Mechanisms in a Murine Model of Allogeneic Bone Marrow Transplantation by Nobuhiro Tsukada, Tetsuji Kobata, Yoshifusa Aizawa, Hideo Yagita, and Ko Okumura Blood Volume 93(8):2738-2747 April 15, 1999 ©1999 by American Society of Hematology

Mortality and body weight during acute GVHD after allo-BMT. Mortality and body weight during acute GVHD after allo-BMT. (A) Lethal GVHD was induced by transfer of B6 BM cells plus 2.5 × 107 spleen cells (B6 BMS) into lethally irradiated BDF1 mice. Recipients of B6 BM cells (B6 BM), B6 T-cell–depleted BM cells (B6 TCD-BM), or syngeneic BDF1 BM cells plus spleen cells (BDF1 BMS) manifested no signs of GVHD and almost all recipients survived more than 80 days, except for 1 recipient of B6 BM. (B and C) Contribution of TNF--, FasL-, and perforin-mediated cytotoxic pathways to lethal acute GVHD. Lethally irradiated BDF1 mice were transplanted with BM cells plus 2.5 × 107 spleen cells from wild-type B6 (B6 BMS), B6-gld (gld BMS), or perforin-deficient (PKO BMS) mice. In another group, B6 BMS recipients were administered with anti–TNF- MoAb (B6 BMS + anti–TNF-). Mortality (B) and body weight (C) were monitored at the indicated days after BMT. Administration of anti–TNF- MoAb to the B6 BMS almost completely ameliorated the mortality and the body weight loss resulted from acute GVHD. Survival of the gld BMS and PKO BMS recipients was 100% and 80%, respectively, on day 80 after BMT. The data represent the results of three similar experiments. Nobuhiro Tsukada et al. Blood 1999;93:2738-2747 ©1999 by American Society of Hematology

Characterization of L1210 murine leukemia and P815 murine mastcytoma cells. Characterization of L1210 murine leukemia and P815 murine mastcytoma cells. (A) L1210 and P815 cells were cultured in the presence of recombinant TNF- for 24 hours and then cell viability was analyzed using the alamar Blue method. Both L1210 and P815 were resistant to TNF-, whereas L929 was susceptible to TNF-. (B)51Cr-labeled L1210 or P815 cells were cocultured with murine FasL transfectant (mFasL/L5178Y) cells at the indicated E/T ratios for 6 hours and then cytotoxicity was measured by51Cr-release assay. (C) Proliferative response of spleen cells obtained from wild-type, gld, or PKO B6 mice against allogeneic L1210 or P815 cells. Spleen cells (2 × 105) were cultured with irradiated L1210 or P815 cells (2 × 104) for 5 days and pulsed with 3H-TdR during the last 16 hours. Spleen cells were prepared from one mouse of each strain and were used immediately after preparation. Data are represented as the mean ± SD of triplicated samples. Spleen cells obtained from each mouse responded equally to L1210 or P815 cells. (D) Killing of L1210 cells by CTL derived from wild-type, gld, and PKO B6 mice. Spleen cells were collected after 5 days of coculture with irradiated L1210 cells as described in (B) and restimulated with irradiated L1210 cells in the presence of 10 U/mL IL-2 for 5 days. CTL activity was tested against 51Cr-labeled L1210 or P815 target cells at the indicated E/T ratios. Although killing activity of CTL derived from gld mice was only slightly diminished as compared with that from wild-type mice, PKO-derived CTL exhibited no significant cytotoxicity against L1210 cells. Data are represented as the mean ± SD of triplicated samples. A representative of three experiments is shown. Nobuhiro Tsukada et al. Blood 1999;93:2738-2747 ©1999 by American Society of Hematology

GVL effect after allo-BMT. GVL effect after allo-BMT. GVL effect was evaluated in BDF1 mice that were inoculated IV with 1 × 104 L1210 cells (A) or 1 × 105 P815 cells (B) 2 days before the BMT as described in Fig 1A. (A) Mice inoculated with L1210 and P815 cells died within 8 and 10 days, respectively, when they received irradiation alone without BMT (no BMT). Transfer of B6 TCD-BM or syngeneic BDF1 BMS resulted in early leukemia relapse. Recipients of B6 BM or BMS survived longer than the above-noted three groups, but all mice died within 60 days. Data represent the results of three similar experiments. Nobuhiro Tsukada et al. Blood 1999;93:2738-2747 ©1999 by American Society of Hematology

Histopathological examination of the liver obtained from normal BDF1 and the recipients of B6 TCD-BM, B6 BM, or B6 BMS in the GVL experiment shown in Fig 3A. Histopathological examination of the liver obtained from normal BDF1 and the recipients of B6 TCD-BM, B6 BM, or B6 BMS in the GVL experiment shown in Fig 3A. (A) Liver section from an age-matched normal BDF1 mouse. (B) Massive leukemia cell infiltration was observed in the liver section from the recipients of B6 TCD-BM at the time of death. (C) Liver section obtained from the recipients of B6 BM on day 28 after BMT showed residual leukemia cells among normal liver tissue. (D) Liver section from the recipients of B6 BMS on day 28 after BMT showed severe mononuclear cell infiltration, but there was no residual leukemia cell in any fields of the section. Each figure shows a representative of three similar experiments. Similar results were also observed by using another tumor P815 cells. Original magnification × 400. Nobuhiro Tsukada et al. Blood 1999;93:2738-2747 ©1999 by American Society of Hematology

Contribution of TNF-–, FasL-, or perforin-mediated cytotoxicity to the GVL effect. Contribution of TNF-–, FasL-, or perforin-mediated cytotoxicity to the GVL effect. GVL effect was evaluated in BDF1 mice that were inoculated IV with 1 × 104 L1210 or 1 × 105 P815 cells 2 days before the BMT as described in Fig1B. (A) Administration of anti–TNF- MoAb to the recipients of B6 BMS resulted in early death within 16 days. Six of 10 gld BMS recipients survived more than 80 days, whereas all B6 BMS or PKO BMS recipients died within 51 days. (B) Similar results were also observed by using another tumor P815 cells. Administration of anti–TNF- MoAb resulted in early death within 24 days. Six of 8 gld BMS recipients survived more than 80 days, whereas all B6 BMS or PKO BMS recipients died within 47 days. Data represent the results of three similar experiments. Nobuhiro Tsukada et al. Blood 1999;93:2738-2747 ©1999 by American Society of Hematology

Histopathological examination of the GVL experiments shown in Fig 5A. Histopathological examination of the GVL experiments shown in Fig 5A. (A) Administration of anti–TNF- MoAb resulted in early death with marked hepatosplenomegaly (left) compared with an age-matched normal mouse (right). The liver section obtained at the time of death showed massive leukemia infiltration (B). (C) Liver section obtained from gld BMS recipients on day 28 showed focal mononuclear infiltration around portal area, but there was no residual leukemia cells in any fields of the section. Residual leukemia cell was not detected in spleen, BM, or peripheral blood. (D) Residual leukemia cells were observed in small areas of the liver section from the PKO BMS recipients. Each figure shows a representative of three similar experiments. Similar results were also observed by using another tumor P815 cells. Original magnification × 400. Nobuhiro Tsukada et al. Blood 1999;93:2738-2747 ©1999 by American Society of Hematology